Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5537565 | Vaccine | 2017 | 8 Pages |
Abstract
In conclusion, simplicity of manufacturing process and low costs of production, coupled with encouraging immunogenicity data, make GMMA an attractive strategy to further investigate for the development of a vaccine against iNTS.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
G. De Benedetto, R. Alfini, P. Cescutti, M. Caboni, L. Lanzilao, F. Necchi, A. Saul, C.A. MacLennan, S. Rondini, F. Micoli,